Gilead's Yescarta eyes first to move up lymphoma ladder in Europe amid busy week at EMA

After leading the CAR-T field to a first-in-class FDA nod for earlier treatment of certain blood cancers, Gilead Sciences’ Yescarta looks on track to cross the finish line first in EU, too.